CagriSema dosage starts at 0.25 mg cagrilintide/0.25 mg semaglutide weekly and escalates to 2.4 mg/2.4 mg. See the full trial schedule and safety notes.
In the REDEFINE clinical trials, the CagriSema dose was 2.4 mg cagrilintide plus 2.4 mg semaglutide, injected under the skin once weekly. That target is reached gradually, because the CagriSema starting dose is 0.25 mg of each peptide per week, with a step up roughly every four weeks. CagriSema is an investigational drug and is not FDA-approved for weight loss or any other use in the United States.
What CagriSema Is and Why the Dose Matters
CagriSema is a fixed-dose combination of two peptides delivered in a single once-weekly injection. Cagrilintide is a long-acting amylin analog, and semaglutide is a GLP-1 receptor agonist, the same drug class as Ozempic and Wegovy.
Because the two peptides act on overlapping appetite and blood sugar pathways, the combination is being studied for greater weight loss than either ingredient alone. The dose matters because the two compounds are locked together in one pen: you cannot raise one without raising the other.
- Cagrilintide: slows stomach emptying and increases fullness signals.
- Semaglutide: reduces appetite and improves blood sugar control.
- Fixed ratio: every escalation step raises both peptides by the same amount.
CagriSema Starting Dose and Dosing Schedule
The CagriSema dosing schedule used in the REDEFINE program escalates in five broad steps, with about four weeks at each level. Escalation continues only if the current dose is tolerated.
| Weeks | Cagrilintide per week | Semaglutide per week | Total peptide |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.25 mg | 0.5 mg |
| 5 to 8 | 0.5 mg | 0.5 mg | 1.0 mg |
| 9 to 12 | 1.0 mg | 1.0 mg | 2.0 mg |
| 13 to 16 | 1.7 mg | 1.7 mg | 3.4 mg |
| 17 and beyond | 2.4 mg | 2.4 mg | 4.8 mg |
Two practical points matter more than the exact numbers. First, this schedule is a ceiling rather than a target, and clinicians routinely hold patients at a lower step when nausea or vomiting appears. Second, skipping steps to speed up results is unsafe, because side effects scale with dose.
How to Read the Escalation Steps
Each row describes a once-weekly injection, not a daily dose. The total peptide column simply adds cagrilintide and semaglutide together, which is a useful way to compare CagriSema with single-agent GLP-1 drugs.
If a dose is missed, trial protocols generally direct participants to take the next scheduled dose rather than doubling up. Real-world prescribing rules may differ once the drug is approved.
How the CagriSema Dose Compares With Other Weight-Loss Drugs
The studied maintenance dose sits in the same range as other injectable weight-loss medications, but the outcomes come from separate trials with different populations. Numbers from separate trials cannot be compared directly.
| Regimen | Reported mean weight loss | Trial |
|---|---|---|
| CagriSema 2.4 mg / 2.4 mg | About 20% to 23% at 68 weeks | REDEFINE 1 |
| CagriSema 2.4 mg / 2.4 mg with type 2 diabetes | About 13.7% | REDEFINE 2 |
| Semaglutide 2.4 mg | About 15% | STEP 1 |
| Tirzepatide 15 mg | About 21% | SURMOUNT-1 |
CagriSema Dosing Chart: Trials vs. Reddit Threads
Search for a cagrisema dosage chart and you will find two very different sources: published trial protocols and anonymous forum posts. Only the trial protocols are backed by controlled data.
Reddit logs are still useful for one thing, which is showing how often people stall at a step or stop treatment because of side effects. Treat those posts as anecdotes rather than instructions.
Always compare any third-party cagrisema dosage chart against the published trial protocol before acting on it. A single user's personal log is not a clinical dosing guide.
What About "CagriSema 10 mg / 10 mg"?
Some people search for a CagriSema 10 mg 10 mg dose after seeing a vial label or a forum post. There is no 10 mg/10 mg maintenance dose in the REDEFINE trials; the studied target is 2.4 mg of each peptide once weekly.
When a supplier lists "10 mg," that number almost always describes the total powder in the vial rather than the amount per injection. Confusing the two can produce a dose several times higher than anything tested in humans.
Is There a CagriSema Dosing Calculator?
There is no validated CagriSema dosing calculator, because the drug is a fixed-dose pen rather than a weight-based injection. Your dose is set by which pen strength you are prescribed, not by your body weight.
Weight-based math does apply to many other injectable peptides, and a bpc-157 dosage chart by weight is a familiar example, but that logic does not transfer to CagriSema. Applying reconstitution math to a drug that was never studied as a powder is a common and preventable error.
Side Effects and Safety Considerations
Gastrointestinal effects are the most common reason people reduce or pause CagriSema. Nausea, vomiting, diarrhea, and constipation usually cluster in the days right after an increase.
- Nausea, vomiting, and diarrhea
- Constipation, bloating, and indigestion
- Injection-site reactions
- Fatigue and headache
GLP-1 and amylin-based drugs also carry class warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, and thyroid C-cell tumors observed in rodents. CagriSema is not recommended during pregnancy, and semaglutide should be stopped well before a planned pregnancy.
Anyone using CagriSema should do so under medical supervision, because the appropriate dose depends on side effects, kidney function, and other health conditions. A licensed clinician can adjust or pause the escalation schedule in ways a forum post cannot.
Gray-Market CagriSema and Other Research Peptides
CagriSema is not sold in pharmacies today, so vials labeled "CagriSema" come from unregulated suppliers with no purity guarantee. Sterility, actual peptide content, and accurate labeling are all unverified in that market.
People comparing research compounds often review several protocols at once, such as bpc-157 and tb-500 dosage for injury, pt-141 dosage, or IGF-1 LR3 dosage per day. None of these compounds is FDA-approved for human use, and self-dosing any of them carries real risk.
If you are considering a GLP-1 or amylin medication, the safer path is a licensed clinician and an approved product, or enrollment in a clinical trial for CagriSema itself.
Frequently Asked Questions
What is the starting dose of CagriSema?
The CagriSema starting dose in the REDEFINE trials was 0.25 mg cagrilintide plus 0.25 mg semaglutide, injected once weekly. The dose was then increased roughly every four weeks until reaching the 2.4 mg/2.4 mg maintenance level, as long as side effects allowed.
What is the maximum CagriSema dose?
The highest dose studied in the REDEFINE program is 2.4 mg cagrilintide plus 2.4 mg semaglutide once weekly. There is no 10 mg/10 mg CagriSema dose in the clinical trial data, and vial labels listing 10 mg usually refer to total powder content, not the amount per injection.
Is CagriSema available in the US?
CagriSema is still an investigational drug and has not been approved by the FDA, so it is not available by prescription in the United States. Vials sold online as CagriSema are unregulated research chemicals, and their content, sterility, and dosing accuracy cannot be verified.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.